Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model.

Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR.

Vet Pathol. 2005 May;42(3):306-14.

PMID:
15872376
2.

Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

Yeh IT, Reddick RL, Kumar AP.

Prostate. 2009 May 15;69(7):755-60. doi: 10.1002/pros.20924.

PMID:
19170049
3.

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ.

Cancer Res. 2001 Mar 1;61(5):2239-49.

5.

Phyllodes tumor of the seminal vesicle: case report and literature review.

Son HJ, Jeong YJ, Kim JH, Chung MJ.

Pathol Int. 2004 Dec;54(12):924-9.

PMID:
15598315
7.

Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen.

Shibata MA, Jorcyk CL, Devor DE, Yoshidome K, Rulong S, Resau J, Roche N, Roberts AB, Ward JM, Green JE.

Carcinogenesis. 1998 Jan;19(1):195-205.

PMID:
9472712
9.

Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice.

Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, Kisiel N, Vujcic S, Mazurchuk RV, Porter CW.

J Biol Chem. 2004 Sep 17;279(38):40076-83.

10.

Mixed epithelial-stromal tumor (MEST) of seminal vesicle: a proposal for unified nomenclature.

Reikie BA, Yilmaz A, Medlicott S, Trpkov K.

Adv Anat Pathol. 2015 Mar;22(2):113-20. doi: 10.1097/PAP.0000000000000057. Review.

PMID:
25664946
11.

Cystosarcoma phyllodes of the seminal vesicle.

Fain JS, Cosnow I, King BF, Zincke H, Bostwick DG.

Cancer. 1993 Mar 15;71(6):2055-61.

12.

MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma.

Leroy X, Ballereau C, Villers A, Saint F, Aubert S, Gosselin B, Porchet N, Copin MC.

Am J Surg Pathol. 2003 Apr;27(4):519-21.

PMID:
12657938
13.

Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma.

Ishii K, Shappell SB, Matusik RJ, Hayward SW.

Lab Invest. 2005 Sep;85(9):1086-103.

15.

Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.

Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.

Prostate. 2008 May 15;68(7):715-27. doi: 10.1002/pros.20689.

16.

Cystic epithelial-stromal tumor of the seminal vesicle.

Mazur MT, Myers JL, Maddox WA.

Am J Surg Pathol. 1987 Mar;11(3):210-7.

PMID:
3030148
17.

Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.

Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS.

Cancer Res. 2002 Mar 1;62(5):1370-6.

18.

An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.

Suttie AW, Dinse GE, Nyska A, Moser GJ, Goldsworthy TL, Maronpot RR.

Toxicol Pathol. 2005;33(3):386-97.

PMID:
15805078
19.

Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist.

Said MM, Hokaiwado N, Tang M, Ogawa K, Suzuki S, Ghanem HM, Esmat AY, Asamoto M, Refaie FM, Shirai T.

Cancer Sci. 2006 Jun;97(6):459-67.

20.

Testicular adenoma and seminal vesicle engorgement in polyomavirus large-T antigen transgenic mice.

Chalifour LE, Mes-Masson AM, Gomes ML, Wang NS.

Mol Carcinog. 1992;5(3):178-89.

PMID:
1375029

Supplemental Content

Support Center